CPBTD
MDGL icon

Central Pacific Bank - Trust Division’s Madrigal Pharmaceuticals MDGL Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,145
Closed -$615K – 896
2026
Q2 		$615K Buy
+1,145
New +$587K 0.06% 287

Other funds holding MDGL

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Central Pacific Bank - Trust Division's MDGL Position: Q3 2026 in Review

Central Pacific Bank - Trust Division sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 1,145 shares — an estimated $615K sold.

Central Pacific Bank - Trust Division first reported a position in MDGL in Q2 2026 and held it in 1 quarter. The position peaked at $615K in Q2 2026. 8 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Central Pacific Bank - Trust Division reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Central Pacific Bank - Trust Division sold 1,145 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $615K.
  • Central Pacific Bank - Trust Division first reported a position in Madrigal Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Central Pacific Bank - Trust Division's Madrigal Pharmaceuticals position peaked at $615K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Central Pacific Bank - Trust Division's 13F filing for Q3 2026, filed 6 Oct 2026.